



HAL
open science

Analysis of the HIV-1 Genomic RNA Dimerization Initiation Site Binding to Aminoglycoside Antibiotics Using Isothermal Titration Calorimetry

Serena Bernacchi, Eric Ennifar

► **To cite this version:**

Serena Bernacchi, Eric Ennifar. Analysis of the HIV-1 Genomic RNA Dimerization Initiation Site Binding to Aminoglycoside Antibiotics Using Isothermal Titration Calorimetry. *RNA Spectroscopy Methods and Protocols*, 2113, pp.237-250, 2020, *Methods in Molecular Biology*,, 10.1007/978-1-0716-0278-2_16 . hal-02911038

HAL Id: hal-02911038

<https://hal.science/hal-02911038>

Submitted on 3 Aug 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Analysis of the HIV-1 Genomic RNA Dimerization Initiation Site Binding to Aminoglycoside Antibiotics Using Isothermal Titration Calorimetry

Serena Bernacchi and Eric Ennifar

Abstract

Isothermal titration calorimetry (ITC) provides a sensitive, powerful, and accurate tool to suitably analyze the thermodynamic of RNA binding events. This approach does not require any modification or labeling of the system under analysis and is performed in solution. ITC is a very convenient technique that provides an accurate determination of binding parameters, as well as a complete thermodynamic profile of the molecular interactions. Here we show how this approach can be used to characterize the interactions between the dimerization initiation site (DIS) RNA localized within the HIV-1 viral genome and aminoglycoside antibiotics. Our ITC study showed that the 4,5-disubstituted 2-desoxystreptamine (2-DOS) aminoglycosides can bind the DIS with a nanomolar affinity and a high specificity.

Key words HIV-1, Viral RNA, Aminoglycosides, Dimerization initiation site, ITC, Thermodynamics, RNA–drug interaction

1 Introduction

Interaction of biological macromolecules either with each other or with small ligands constitutes the basis for molecular recognition. The development of the approaches providing a detailed understanding of these interactions at the molecular level is required to facilitate the design and development of drugs. In this frame, the isothermal titration calorimetry (ITC) is an equilibrium solution technique that directly *characterizes* all parameters regulating the molecular interactions [1–4]. In a typical experiment, aliquots of a titrant in the syringe are injected into the cell containing the sample. Upon each titration, the amount of heat either released or absorbed during the binding event is measured, leading in one single experiment the determination of all the binding parameters: the equilibrium dissociation constant (K_d), the reaction stoichiometry (n), the binding enthalpy (ΔH), the binding entropy (ΔS), and the Gibbs free energy change (ΔG). Moreover, the analysis at

several temperatures gives also access to the heat capacity change (ΔC_p). Importantly, thermodynamic analysis can give access to structural data and hence provides information on hydrogen bonding, hydrophobic interactions, and charge–charge interactions. A serious advantage of ITC over other alternative approaches is that ITC is a true solution technique which does not require any modification, labelling, or immobilization of any partner (truly label-free) and that there is no restriction in the molecular weight of the reagents or in the choice of the buffer composition. Since the measured enthalpy results not only from the heat of the binding events but also from other heat sources such as solvent effects and/or heat of dilution, one has to pay attention to prevent any buffer mismatch between the syringe and the sample cell (*see Note 1*). Importantly, the application field of ITC has been recently extended to kinetics, in addition to thermodynamics, by the development of kinITC [5–9]. This method leads to the determination of on- and off-rates close to those obtained by surface plasmon resonance [10, 11].

In this chapter, we provide a detailed protocol for the characterization of interactions between a fragment of viral RNA with aminoglycoside drugs. ITC is a well-adapted technique for the study of RNA/ligand interactions [12–17]. The RNA used in this chapter is a synthetic 23-nucleotide containing the HIV-1 genomic RNA dimerization initiation site (DIS). Dimerization of the genomic RNA is a crucial step of the HIV-1 retrovirus replication cycle. The DIS is a highly conserved stem–loop sequence located in the 5'-untranslated region of the viral genome which is essential for genome dimerization [18, 19]. A six-nucleotide palindromic sequence within the DIS promotes genome dimerization by forming a loop–loop complex (or kissing-loop complex) [20–23]. This initial kissing-loop complex is further stabilized in vitro into an extended duplex form by extension of interstrand Watson–Crick base pairs [24–28]. X-ray structures of the DIS as a loop–loop complex [29, 30] and as an extended duplex [31, 32] revealed striking resemblance with the bacterial 16 S ribosomal A site, which is the natural target of aminoglycoside antibiotics, thus opening the opportunity of targeting the HIV DIS using such compounds [33, 34]. In this frame, ITC analysis showed that the 4,5-disubstituted 2-desoxystreptomine (2-DOS) aminoglycosides, but not 4,6-disubstituted 2-DOS, can bind specifically DIS dimers. Binding parameters revealed that the specific interaction between aminoglycosides and DIS kissing loop is ensured by rings I, II, and III, while rings IV and V enhanced affinity through unspecific interaction with sugar phosphate backbone. The RNA determinants of this interaction were also investigated, and we could show that DIS hairpin monomer, as well as the HIV-1 subtype-B DIS sequence, is not specifically recognized by aminoglycosides. This exhaustive ITC analysis of the binding and thermodynamic

parameters contributed to solve crystal structures of the DIS kissing loop and extended duplex in complex with several 4,5-disubstituted 2-DOS aminoglycosides [35–39].

2 Materials

2.1 Instrumentation

1. iTC₂₀₀, PEAQ-ITC (MicroCal, Malvern Panalytical, Malvern, UK) or equivalent highly sensitive isothermal titration calorimeter (*see Note 2*).
2. Refrigerated centrifuge for a rotor adapted for 50-mL Falcon tubes.
3. Nanodrop ND-1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) or equivalent.
4. Dry bath for 90 °C incubation of Eppendorf tubes.

2.2 Instrument Accessories

1. Hamilton glass loading syringes for calorimeter.
2. BD Luer-Lok 1-mL syringe.

2.3 Sample Preparation

1. 23-mer HIV-1 RNA (sequence 5'-CUGCUUGAAGUGCACACAGCAAG3') was chemically synthesized at the 1 μmol scale and purified (>98%) as described previously [32].
2. Lividomycin, neomycin, or paromomycin sulfate, powder. These aminoglycosides were purchased from Sigma-Aldrich and used without further purification. Paromomycin is shown in this example.
3. Amicon Ultra-4 centrifugal filter unit 10,000 MWCO (Millipore, Billerica, MA, USA).
4. 10× ITC buffer: 250 mM potassium chloride, 20 mM magnesium chloride, 200 mM sodium cacodylate, pH 7.0 (*see Note 3*). Prepare 10 mL.
5. 1× ITC buffer: 150 mM potassium chloride, 2 mM magnesium chloride, 20 mM sodium cacodylate, pH 7.0. Prepare 10 mL.

3 Methods

3.1 Sample Preparation

- For each experiment, 300 μL of RNA at 10–30 μM should be prepared.
1. RNA is aliquoted in 3 Eppendorf tubes, each tube containing 1 mL of RNA at 2 μM in pure water (*see Note 4*).
 2. Heat RNA sample for 5 min at 90 °C and snap cool in water on ice at 0 °C for 10 min.

3. Add 111 μL of $10\times$ ITC buffer in each Eppendorf tube. 121
4. RNA sample is concentrated to a final volume of $\sim 300\ \mu\text{L}$ using an Amicon Ultra-4 concentrator. Centrifuge for ~ 10 min at $4500\ g$ at $10\ ^\circ\text{C}$ (recommended speed in a swinging rotor). Higher temperature should be avoided in order to prevent the conversion from the loop-loop complex RNA to the extended duplex form [40]. 122-124-125-126-127
5. Check the absorbance at 260 nm using a spectrophotometer (take a full spectrum and not a single value). Here a final concentration of $16.8\ \mu\text{M}$ (in strand) is obtained. 128-129-130
6. Prepare 1 mL of aminoglycoside solution at a $400\ \mu\text{M}$ concentration in $1\times$ ITC buffer. This chapter shows an example with the paromomycin aminoglycoside. The optimal aminoglycoside concentration may be different for another compound. 131-132-133-134-135

3.2 Designing a Typical ITC Experiment

3.2.1 Experimental Considerations

During an ITC experiment, aliquots of ligand are injected into the sample cell. The interaction between the ligand and the molecule in the cell induces the release (exothermic interaction) or absorption (endothermic interaction) of heat which is directly measured by the calorimeter. The titration curve of kcal mol^{-1} vs. molar ratio (ligand/sample) is generated by the integration of each heat pulse with time and normalized for concentration. After the fitting of the resulting isotherm with a binding model, the affinity constant ($K_a = 1/K_d$), the stoichiometry (n), and the enthalpy of interaction (ΔH) are obtained. The Gibbs free energy change (ΔG) and the entropy change (ΔS) are deduced via the thermodynamic relationships: 136-137-138-139-140-141-142-143-144-145-146-147

$$\Delta G = -RT \ln K_a = RT \ln K_d$$

$$\Delta G = \Delta H - T\Delta S \quad 148-149$$

The determination of the appropriate concentration of the component placed in the sample cell (MT) depends on the binding affinity, the stoichiometry, and the heat of binding ΔH . If the Wiseman coefficient ($\epsilon = n \cdot K_a \cdot MT$) calculated is in the 1–1000 range (preferably between 10 and 500) [3], a sigmoid is then obtained, and this allows the determination of the accurate binding constant and ΔH . 150-151-152-153-154-155-156

In general the required concentrations of sample in the cell are ranging from 5 to $100\ \mu\text{M}$. Typical concentration for the ligand in the injection syringe is normally 10–20 times higher (and even higher in the case of low Wiseman ϵ value experiments [41–43]). These conditions will ensure that the cell sample will become saturated at the end of the titration experiment. Therefore, the sample requirement in order to perform an ITC experiment under ideal conditions ($\epsilon \sim 100$) might be significant for biological low affinity systems. A crucial point to obtain high-quality ITC 157-158-159-160-161-162-163-164-165

experiments is to minimize the heat signal originated from mismatches between the solutions that are mixed (*see Note 1*). For this reason, it is imperative to prepare the two samples (from the syringe and the cell) rigorously in the same buffer.

3.2.2 Instrument Parameters

On iTC₂₀₀ and PEAQ-ITC microcalorimeters, the glass titration syringe holds up to 40 μL . Typical injections are ranging from 0.25 to 2 μL . The number of injections per experiment should be set in order to saturate the RNA at the end of the titration (a final molar ratio of 3–5 is acceptable in most situations). The injection speed should be 0.5 $\mu\text{L s}^{-1}$. The spacing between the injections is a frequently overlooked parameter, leading to truncated peaks and erroneous data if a complete return to the baseline is not achieved. We have shown that the time required for equilibration is strongly dependent on the rate constants k_{on} and k_{off} of each system [9]. The spacing value can be set to 120 s by default on the iTC₂₀₀, but it might be increased to 240 s or even longer in some situations [5, 10]. The filter value on iTC₂₀₀ instrument corresponds to the integration time that will be used to produce a single data point. Usually the filter period is set to 5 by default; however, setting 1 or 2 for a better sampling of each peak in view of performing a kinetic analysis of the thermodynamic data is also possible [6, 9]. This value is fixed to 1 on the PEAQ-ITC instrument and cannot be modified.

The feedback mode of the calorimeter setup should be set to “high gain,” yielding the fastest response time. The “reference power” value corresponds to the baseline (in $\mu\text{Cal s}^{-1}$) during the experiment. In the high gain mode, the instrument’s reference power ranges from 0 to 12.25 $\mu\text{Cal s}^{-1}$ for the iTC₂₀₀. In most cases, the reference power can be fixed to 5 $\mu\text{Cal s}^{-1}$. The stirring speed depends on the syringe geometry. It should be set to 1000 rpm for straight-bladed syringes on iTC₂₀₀, but this value can be reduced to 750 rpm for helical-bladed syringe available on both iTC₂₀₀ and PEAQ-ITC (*see Note 5*).

Most experiments are performed between 4 and 37 °C (the instrument’s theoretical operating range is 2–80 °C, but extremes are not usable in practice). The choice of the experiment temperature is often overlooked, while it might be crucial to optimize results in some situations. Indeed, most biomolecular interactions are characterized by a temperature dependence of the ΔH due to a negative heat capacity change (*see Note 6*). In addition, the van’t Hoff relationship

$$\partial \ln K_{\text{d}} / \partial T = -\Delta H / (RT^2)$$

also shows that K_{d} is affected by temperature change. Changing the cell temperature is thus an easy way to play on the Wiseman c value.

3.3 Performing the ITC Experiment

Below is described the procedure for an iTC ₂₀₀ microcalorimeter.	211
The experiment will be performed at 25 °C.	212
1. Fill the reference cell with ultrapure water using a 0.5-mL glass Hamilton syringe.	213 214
2. In the instrument controls tab, set the temperature at 25 °C in “Thermostat Control,” and click “Set Jacket Temp.”	215 216
3. Rinse the sample cell, two or three times, with 1 × ITC buffer.	217
4. Warm up the RNA sample at 25 °C before loading in the sample cell.	218 219
5. Gently load the sample cell with 300 μL of RNA sample. The small excess should be removed. The final sample volume in the cell is ~280 μL. Care must be taken to avoid bubble formation in the sample cell.	220 221 222 223
6. To load the titration syringe, place a microcentrifuge tube with at least 70 μL of aminoglycoside sample at 400 μM. Place the syringe titration above the microcentrifuge tube in order that the tip of the syringe is immersed in ligand solution. Manual loading of the syringe is recommended since it is faster and safer than the semiautomatic procedure on the iTC ₂₀₀ , especially if the sample is viscous (i.e., with a buffer containing some glycerol or with highly concentrated protein). Connect the BD syringe to the titration syringe and load the sample manually by aspiration into the titration syringe (before aspiration, make sure that the plunger is in the open position). When the sample gets to the plunger, click “Close Fill Port” in the instrument controls tab; this will move the plunger tip down and block the fill port. Perform the “purge/refill” procedure to remove small air bubbles in the syringe. Unplug the BD syringe from the titration syringe.	224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239
7. Place the titration syringe into the sample cell.	240
8. Set the reference power to 5 μCal s ⁻¹ .	241
9. Set the initial delay to 100 s and the stirring speed to 1000 rpm or 750 rpm depending on the syringe geometry.	242 243
10. Set the number of injections to 28, the sample cell concentration to 0.0168 mM, and the concentration in the syringe to 0.4 mM. This ensures a final molar ratio of ~5, required in such RNA/ligand experiments.	244 245 246 247
11. Set the titration parameters (the number and volume of the injections as well as the spacing between two injections) in the “Injection Parameters” window into the “Advanced Experimental Design” tab. Set the first injection volume to 0.3 μL (<i>see Note 7</i>) and the next injection volume to 1.5 μL. Set the spacing between each injection to 150 s.	248 249 250 251 252 253

12. Press the “Start” button to begin the experiment. The experiment will start when both cells are thermostated at 25 °C. 254-255
13. A blank experiment should be also performed by injecting aminoglycoside into 1× ITC buffer without RNA, in order to subtract the heat of dilution from the reaction heat data. 256-258


3.4 ITC Data Analysis

Various software are available for ITC data processing: MicroCal Origin 7 (VP-ITC and iTC₂₀₀ from MicroCal); NanoAnalyze (TA Instrument); AFFINImeter [8]; the NITPIC, SEDPHAT, and GUSSI package [44, 45], or the MicroCal PEAQ-ITC analysis software (Malvern PEAQ-ITC). ITC data analysis using the MicroCal Origin7 software was previously described in details in [46]. 260-265

Here we will describe the procedure for data processing using the MicroCal PEAQ-ITC analysis software provided with the PEAQ-ITC instrument. 266-268

1. Open the software and select both the RNA–ligand titration and the blank experiment (use the “Ctrl” key to select both files). They are quickly processed and integrated by the software and integrated heats are displayed on the left tab (Fig. 1). Binding is detected for the RNA/ligand titration (“Binding” is displayed in green, Fig. 1a), whereas “No binding” is displayed in orange for the blank experiment (Fig. 1b). 269-275
2. On the right arrowhead of the blank experiment, change “No binding” for “Control” (now displayed in blue). 276-277
3. On the main “Fitting Model” window, change the fitting model from “One Set of Sites” to “Two Sets of Sites” (see Note 8). 278-280
4. On top of the main window, change from “Overview” to “Adjust Baseline.” This tab allows to manually correct integration heat for each data point (Fig. 2). 281-283
5. The “Time Factor” parameter on the bottom of the window might be useful if the baseline is not stable (large oscillation of the baseline due to air-conditioning, for instance), but 5 is generally a good standard value. 284-287
6. The number of points per injection is set by default to 25, but this can be changed if necessary. 288-289
7. Baseline for the RNA/ligand experiment and the buffer/ligand control can be adjusted, if necessary. This is generally not required in good experimental conditions: well-maintained instrument, samples without aggregates and injections without bubbles, and no heat perturbation around the instrument. 290-294
8. On top of the main window, change from “Adjust Baseline” to “Assign Control.” On “Control Parameter,” change from “Fitted Offset” to “Single.” The control experiment is then automatically selected. The “Line” Method is generally 295-298

a



b




Fig. 1 Screenshot of the “Overview” tab after selection of the RNA/ligand (a) and the blank (b) experiment

preferable over the “Point-to-point” and “Mean” ones 299
 (Fig. 3). In the absence of control experiment, it is possible 300
 to use the heat of dilution from the last injections of the 301
 experiment, provided the RNA oversaturated with ligand. It 302
 is however highly recommended to perform a control experi- 303
 ment to obtain more accurate results. 304




Fig. 2 Screenshot of the “Adjust Baseline” tab. The blue area corresponds to the integrated heat. It is possible to adjust the baseline by moving individually each point and the markers. Individual points can be excluded (or included) on the top-right part of the window




Fig. 3 Screenshot of the “Assign Control” tab. On the left part are shown the integrated heats for the experiment. On the right part are shown the integrated heats for the blank experiment and the corrected integrated heats for the experiment with RNA as well




Fig. 4 Screenshot of the “Adjust Fit” tab

9. On top of the main window, change from “Assign Control” to “Adjust Fit.” Fitted parameters can be adjusted here (Fig. 4). Here, N_1 (which corresponds to the stoichiometry of the first class of binding sites) is very close to 1.0 (as expected since the RNA dimer binds two aminoglycoside ligands), showing that concentrations of the RNA and ligand were correctly estimated and that the RNA is properly folded. This binding site corresponds to the specific binding site and entails the highest affinity ($K_{d1} = 112 \text{ nM}$, $\Delta H = -9.8 \text{ kcal mol}^{-1}$). The stoichiometry of the second set of binding sites, N_2 , is relevant of unspecific binding due to electrostatic interactions with the lowest affinity ($K_{d2} = 40 \text{ }\mu\text{M}$, $\Delta H = -1.6 \text{ kcal mol}^{-1}$).
10. It is important to check errors on refined parameters! Indeed, in this model, the high correlation between the different fitted parameters could lead to multiple equivalent solutions.
11. On top of the main window, change from “Adjust Fit” to “Result Table.” To visualize correlation between fitted parameters, click on “Show Errors” in the bottom of the window. The “dependency” value should be examined for all refined parameters (closer to 0 is better; closer to 1.0 is worst).
12. Select the “Final Figure” tab to display a publication quality figure (Fig. 5) which can be easily exported in various graphical formats.

305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328




Fig. 5 Screenshot of the “Presentation” tab, showing the final figure ready to be exported for publication

4 Notes

329

1. Buffer mismatch is due to differences between the ligand and the sample solution, as well as any difference in pH, salt, glycerol concentration, buffer concentration, or additives. In order to minimize these differences, interactants must be prepared in identical buffers or dialyzed against the same buffer. 330-334
2. Since microcalorimeter (especially iTC₂₀₀) is very sensitive to temperature variations, it is highly recommended to place the instrument far away from any airflow, especially air-conditioning, and in a room exposed to minimal temperature changes (avoid heaters, large windows, or other instruments generating lots of heat such as freezers). The instrument should be regularly and meticulously cleaned. 336-342
3. Low-salt conditions were chosen at this temperature to prevent conversion of the loop–loop dimer into the extended duplex dimer [40]. 343-345
4. RNA concentration at this step should be less than ~3 μM in order to prevent formation of extended duplex dimers as observed in [40]. 346-348
5. Although the reduction of the stirring speed improves the baseline stability, it might introduce artifacts due to insufficient mixing of the injected ligand. 349-351

6. Heat capacity change is defined by the relationship: 352

$$\Delta C_p = (\delta\Delta H/\delta T) \quad 353$$

The heat capacity change is generally negative and associated to a local folding following binding [47]. It is a valuable tool for optimizing the study of any binding event: for an exothermic reaction, ΔH will be more negative at 35 °C than 25 °C and, consequently, the signal will be increased at 35 °C. In some situations, no signal can be detected by ITC. This can result from athermal reactions (ΔH is null in the conditions of the experiment) where the interaction exists, but cannot be detected by ITC (an example is provided in [48]). In such situations, the change in temperature may allow the interaction to be observed due to the heat capacity change of the system. 354
355
356
357
358
359
360
361
362
363
364

7. A first small injection (0.3–0.5 μL) is performed at the beginning of the titration. It will be discarded during data analysis because it is generally affected by error due to sample dilution during the equilibration procedure and to the backlash of the screw mechanism of the syringe motor. 365
366
367
368
369

8. Since the aminoglycoside ligand is positively charged, the RNA/aminoglycoside interaction in this example is characterized by a highly specific interaction coexisting with unspecific interactions due to electrostatic interactions. These unspecific interactions can be strongly reduced by increasing salt concentrations (the specific interaction is also reduced, however). This situation holds true for most of RNA/ligand interactions. 370
371
372
373
374
375
376

377 References

- 379 1. Leavitt S, Freire E (2001) Direct measurement of protein binding energetics by isothermal titration calorimetry. *Curr Opin Struct Biol* 11:560–566 400
- 380
381
382
- 383 2. Privalov PL, Dragan AI (2007) Microcalorimetry of biological macromolecules. *Biophys Chem* 126:16–24 401
- 384
385
- 386 3. Velazquez Campoy A, Freire E (2005) ITC in the post-genomic era...? *Priceless. Biophys Chem* 115:115–124 402
- 387
388
- 389 4. Wiseman T, Williston S, Brandts JF, Lin LN (1989) Rapid measurement of binding constants and heats of binding using a new titration calorimeter. *Anal Biochem* 179:131–137 403
- 390
391
392
- 393 5. Bec G, Meyer B, Gerard MA, Steger J, Fauster K, Wolff P, Burnouf D, Micura R, Dumas P, Ennifar E (2013) Thermodynamics of HIV-1 reverse transcriptase in action elucidates the mechanism of action of non-nucleoside inhibitors. *J Am Chem Soc* 135:9743–9752 404
- 394
395
396
397
398
399
6. Dumas P, Ennifar E, Da Veiga C, Bec G, Palau W, Di Primo C, Pineiro A, Sabin J, Munoz E, Rial J (2016) Extending ITC to kinetics with kinITC. *Methods Enzymol* 567:157–180 405
7. Munoz E, Sabin J, Rial J, Perez D, Ennifar E, Dumas P, Pineiro A (2019) Thermodynamic and kinetic analysis of isothermal titration calorimetry experiments by using KinITC in AFFINImeter. *Methods Mol Biol* 1964:225–239 406
8. Pineiro A, Munoz E, Sabin J, Costas M, Bastos M, Velazquez-Campoy A, Garrido PF, Dumas P, Ennifar E, Garcia-Rio L, Rial J, Perez D, Fraga P, Rodriguez A, Coteló C (2019) AFFINImeter: a software to analyze molecular recognition processes from experimental data. *Anal Biochem* 577:117–134 407
9. Burnouf D, Ennifar E, Guedich S, Puffer B, Hoffmann G, Bec G, Disdier F, Baltzinger M, Dumas P (2012) kinITC: a new method for obtaining joint thermodynamic and kinetic 408
409
410
411
412
413
414
415
416
417
418
419
420

- 421 data by isothermal titration calorimetry. *J Am*
422 *Chem Soc* 134:559–565
- 423 10. Guedich S, Puffer-Enders B, Baltzinger M,
424 Hoffmann G, Da Veiga C, Jossinet F,
425 Thore S, Bec G, Ennifar E, Burnouf D,
426 Dumas P (2016) Quantitative and predictive
427 model of kinetic regulation by *E. coli* TPP
428 riboswitches. *RNA Biol* 13:373–390
- 429 11. Zihlmann P, Silbermann M, Sharpe T, Jiang X,
430 Muhlethaler T, Jakob RP, Rabbani S, Sager CP,
431 Frei P, Pang L, Maier T, Ernst B (2018)
432 KinITC—one method supports both thermody-
433 namic and kinetic SARs as exemplified on
434 FimH antagonists. *Chemistry*
435 24:13049–13057
- 436 12. Barbieri CM, Srinivasan AR, Pilch DS (2004)
437 Deciphering the origins of observed heat
438 capacity changes for aminoglycoside binding to
439 prokaryotic and eukaryotic ribosomal RNA
440 a-sites: a calorimetric, computational, and
441 osmotic stress study. *J Am Chem Soc*
442 126:14380–14388
- 443 13. Feig AL (2007) Applications of isothermal
444 titration calorimetry in RNA biochemistry and
445 biophysics. *Biopolymers* 87:293–301
- 446 14. Feig AL (2009) Studying RNA-RNA and
447 RNA-protein interactions by isothermal titra-
448 tion calorimetry. *Methods Enzymol*
449 468:409–422
- 450 15. Kaul M, Pilch DS (2002) Thermodynamics of
451 aminoglycoside-rRNA recognition: the bind-
452 ing of neomycin-class aminoglycosides to the
453 A site of 16S rRNA. *Biochemistry*
454 41:7695–7706
- 455 16. Pilch DS, Kaul M, Barbieri CM, Kerrigan JE
456 (2003) Thermodynamics of aminoglycoside-
457 rRNA recognition. *Biopolymers* 70:58–79
- 458 17. Salim NN, Feig AL (2009) Isothermal titration
459 calorimetry of RNA. *Methods* 47:198–205
- 460 18. Haddrick M, Lear AL, Cann AJ, Heaphy S
461 (1996) Evidence that a kissing loop structure
462 facilitates genomic RNA dimerisation in
463 HIV-1. *J Mol Biol* 259:58–68
- 464 19. Paillart J-C, Berthoux L, Ottmann M, Darlix
465 J-L, Marquet R, Ehresmann C, Ehresmann B
466 (1996) A dual role of the dimerization initia-
467 tion site of HIV-1 in genomic RNA packaging
468 and proviral DNA synthesis. *J Virol*
469 70:8348–8354
- 470 20. Laughrea M, Jetté L (1994) A 19-nucleotide
471 sequence upstream of the 5' major splice donor
472 site is part of the dimerization domain of
473 human immunodeficiency virus 1 genomic
474 RNA. *Biochemistry* 33:13464–13474
- 475 21. Muriaux D, Girard PM, Bonnet-Mathonière B,
476 Paoletti J (1995) Dimerization of HIV-1
477 RNA at low ionic strength. *J Biol Chem*
478 270:8209–8216
- 479 22. Paillart JC, Skripkin E, Ehresmann B,
480 Ehresmann C, Marquet R (1996) A loop-loop
481 “kissing” complex is the essential part of the
482 dimer linkage of genomic HIV-1 RNA. *Proc*
483 *Natl Acad Sci U S A* 93:5572–5577
- 484 23. Skripkin E, Paillart JC, Marquet R,
485 Ehresmann B, Ehresmann C (1994) Identifica-
486 tion of the primary site of the human immuno-
487 deficiency virus type I RNA dimerization
488 *in vitro*. *Proc Natl Acad Sci U S A*
489 91:4945–4949
- 490 24. Laughrea M, Jetté L (1996) Kissing-loop
491 model of HIV-1 genome dimerization: HIV-1
492 RNA can assume alternative dimeric forms, and
493 all sequences upstream or downstream of hair-
494 pin 248–271 are dispensable for dimer forma-
495 tion. *Biochemistry* 35:1589–1598
- 496 25. Muriaux D, Fossé P, Paoletti J (1996) A kissing
497 complex together with a stable dimer is
498 involved in the HIV-1_{Lai} RNA dimerization
499 process *in vitro*. *Biochemistry* 35:5075–5082
- 500 26. Rist MJ, Marino JP (2002) Mechanism of
501 nucleocapsid protein catalyzed structural
502 isomerization of the dimerization initiation
503 site of HIV-1. *Biochemistry* 41:14762–14770
- 504 27. Takahashi KI, Baba S, Chattopadhyay P,
505 Koyanagi Y, Yamamoto N, Takaku H, Kawai
506 G (2000) Structural requirement for the
507 two-step dimerization of human immunodef-
508 ciency virus type 1 genome. *RNA* 6:96–102
- 509 28. Takahashi KI, Baba S, Koyanagi Y,
510 Yamamoto N, Takaku H, Kawai G (2001)
511 Two basic regions of NCp7 are sufficient for
512 conformational conversion of HIV-1 dimeriza-
513 tion initiation site from kissing-loop dimer to
514 extended-duplex dimer. *J Biol Chem*
515 276:31274–31278
- 516 29. Ennifar E, Dumas P (2006) Polymorphism of
517 bulged-out residues in HIV-1 RNA DIS kiss-
518 ing complex and structure comparison with
519 solution studies. *J Mol Biol* 356:771–782
- 520 30. Ennifar E, Walter P, Ehresmann B,
521 Ehresmann C, Dumas P (2001) Crystal struc-
522 tures of coaxially stacked kissing complexes of
523 the HIV-1 RNA dimerization initiation site.
524 *Nat Struct Biol* 8:1064–1068
- 525 31. Ennifar E, Walter P, Dumas P (2010) Cation-
526 dependent cleavage of the duplex form of the
527 subtype-B HIV-1 RNA dimerization initiation
528 site. *Nucleic Acids Res* 38:5807–5816
- 529 32. Ennifar E, Yusupov M, Walter P, Marquet R,
530 Ehresmann B, Ehresmann C, Dumas P (1999)
531 The crystal structure of the dimerization initia-
532 tion site of genomic HIV-1 RNA reveals an

- 533 extended duplex with two adenine bulges. 573
534 Structure 7:1439–1449 574
- 535 33. Ennifar E, Paillart JC, Marquet R, 575
536 Ehresmann B, Ehresmann C, Dumas P, Walter 576
537 P (2003) HIV-1 RNA dimerization initiation 577
538 site is structurally similar to the ribosomal A 578
539 site and binds aminoglycoside antibiotics. J 579
540 Biol Chem 278:2723–2730 580
- 541 34. Bernacchi S, Freisz S, Maechling C, Spiess B, 581
542 Marquet R, Dumas P, Ennifar E (2007) Ami- 582
543 noglycoside binding to the HIV-1 RNA dimer- 583
544 ization initiation site: thermodynamics and 584
545 effect on the kissing-loop to duplex conversion. 585
546 Nucleic Acids Res 35:7128 586
- 547 35. Ennifar E, Aslam MW, Strasser P, Hoffmann G, 587
548 Dumas P, van Delft FL (2013) Structure- 588
549 guided discovery of a novel aminoglycoside 589
550 conjugate targeting HIV-1 RNA viral genome. 590
551 ACS Chem Biol 8:2509–2517 591
- 552 36. Ennifar E, Paillart JC, Bernacchi S, Walter P, 592
553 Pale P, Decout JL, Marquet R, Dumas P 593
554 (2007) A structure-based approach for target- 594
555 ing the HIV-1 genomic RNA dimerization ini- 595
556 tiation site. Biochimie 89:1195–1203 596
- 557 37. Ennifar E, Paillart JC, Bodlenner A, Walter P, 597
558 Weibel JM, Aubertin AM, Pale P, Dumas P, 598
559 Marquet R (2006) Targeting the dimerization 599
560 initiation site of HIV-1 RNA with aminoglyco- 600
561 sides: from crystal to cell. Nucleic Acids Res 601
562 34:2328–2339 602
- 563 38. Freisz S, Lang K, Micura R, Dumas P, Ennifar 603
564 E (2008) Binding of aminoglycoside antibi- 604
565 otics to the duplex form of the HIV-1 genomic 605
566 RNA dimerization initiation site. Angew Chem 606
567 Int Ed Engl 47:4110–4113 607
- 568 39. Bodlenner A, Alix A, Weibel JM, Pale P, 608
569 Ennifar E, Paillart JC, Walter P, Marquet R, 609
570 Dumas P (2007) Synthesis of a neamine 610
571 dimer targeting the dimerization initiation site 611
572 of HIV-1 RNA. Org Lett 9:4415–4418
40. Bernacchi S, Ennifar E, Toth K, Walter P, 573
Langowski J, Dumas P (2005) Mechanism of 574
hairpin-duplex conversion for the HIV-1 575
dimerization initiation site. J Biol Chem 576
280:40112–40121 577
41. Tellinghuisen J (2008) Isothermal titration cal- 578
orimetry at very low c. Anal Biochem 579
373:395–397 580
42. Tellinghuisen J (2016) Analysis of multitem- 581
perature isothermal titration calorimetry data 582
at very low c: global beats van't Hoff. Anal 583
Biochem 513:43–46 584
43. Turnbull WB, Daranas AH (2003) On the 585
value of c: can low affinity systems be studied 586
by isothermal titration calorimetry? J Am 587
Chem Soc 125:14859–14866 588
44. Brautigam CA, Zhao H, Vargas C, Keller S, 589
Schuck P (2016) Integration and global analy- 590
sis of isothermal titration calorimetry data for 591
studying macromolecular interactions. Nat 592
Protoc 11:882–894 593
45. Keller S, Vargas C, Zhao H, Piszczek G, Brau- 594
tigam CA, Schuck P (2012) High-precision 595
isothermal titration calorimetry with auto- 596
mated peak-shape analysis. Anal Chem 597
84:5066–5073 598
46. Da Veiga C, Mezher J, Dumas P, Ennifar E 599
(2016) Isothermal titration calorimetry: 600
assisted crystallization of RNA-ligand com- 601
plexes. Methods Mol Biol 1320:127–143 602
47. Spolar RS, Record MT Jr (1994) Coupling of 603
local folding to site-specific binding of proteins 604
to DNA. Science 263:777–784 605
48. Ramirez J, Recht R, Charbonnier S, Ennifar E, 606
Atkinson RA, Trave G, Nomine Y, Kieffer B 607
(2015) Disorder-to-order transition of MAGI- 608
1 PDZ1 C-terminal extension upon peptide 609
binding: thermodynamic and dynamic insights. 610
Biochemistry 54:1327–1337 611